5 Gaps in Standard Cardiac Care. One Enzyme That Fills Them.

In 22 years of practice I have had a version of the same conversation hundreds of times. A patient comes in — sometimes a few weeks after a stent, sometimes a few months after their father had one — and they ask me a quiet question. They ask it in different words, but it is always the same question.

What can I actually do, beyond the prescription, so this doesn’t happen to me?

So I am writing it down. Below are the five things I tell patients who walk into my office with that question — and at the end, the one thing I now recommend to almost all of them.

Aspirin stops platelets from sticking together. That helps prevent new clots from forming. But it does nothing about the buildup that is already inside the artery walls.

That buildup is made of a protein called fibrin. It layers on year after year. Aspirin does not break it down. It was never designed to.

Nattokinase is a Japanese enzyme that has been studied for over forty years for one specific ability: breaking down fibrin directly. Where aspirin prevents new clots, nattokinase supports the breakdown of what is already there.

Two different jobs. Most cardiac care only covers one of them.

Statins lower LDL cholesterol. The data on that is strong, and for the right patient, the protective benefit is real.

Here is what the printout your cardiologist handed you does not say. Statins block an enzyme called HMG-CoA reductase. That enzyme is part of a pathway in your body called the mevalonate pathway. The mevalonate pathway makes cholesterol — which is what we want the statin to interrupt. But the same pathway also makes a molecule called CoQ10, which every cell in your heart, brain, and muscles uses to produce energy.

So a side effect of statin therapy, well documented since the 1990s, is the gradual depletion of CoQ10. The exact molecule the heart muscle needs most.

This is not a controversial claim. The man who first synthesized CoQ10 at Merck in 1958, Dr. Karl Folkers, was raising the alarm about this interaction decades ago. American cardiology, however, still does not routinely test patient CoQ10 levels or recommend supplementation alongside statin therapy. Most patients on a statin have never heard the word.

If a patient on a statin is telling me they feel tired, foggy, or weaker than they used to — that is the first place I look.

Cardiac surgery is a remarkable thing. A stent in 2026 is a small miracle of engineering. A bypass takes blood around a blockage and gives the heart a clean path again. If you needed one, you should be grateful you got it.

It is also worth being honest about what the procedure did and did not do. A stent widens one specific stretch of one specific artery. A bypass routes around one specific obstruction. Neither procedure addresses the systemic blood, vessel, and inflammatory environment that produced the blockage in the first place.

Which is why the recurrence rate after a first cardiac event is what it is.

This is the part most patients are not told plainly. The procedure was the urgent fix. It is not the long-term plan.

I want to defend my colleagues for a moment. The reason your cardiologist did not have a longer conversation with you about long-term cardiovascular support is almost never that they did not care. It is structural.

The average cardiology follow-up appointment in the United States is between eight and fourteen minutes. In that window, the cardiologist needs to review your medications, examine you, look at any new test results, document everything in the chart for billing and compliance, answer any urgent questions, and get to the next patient. There is no room left for an unhurried conversation about what you can do at home for the next thirty years.

This is not a moral failure of cardiology. It is a structural feature of how American medicine is paid. But it does mean that the part of cardiovascular care that involves what to do next almost always falls to the patient to figure out alone.

This is the part of the conversation that, in a longer appointment, I would spend the most time on.

Almost no American cardiologist has heard of nattokinase. The reason is structural, not medical. A large clinical trial in the United States costs between fifty and a hundred million dollars to conduct, and no pharmaceutical company will spend that money on a substance derived from a food, because food cannot be patented, and what cannot be patented cannot be sold as a prescription. So the research has been done in Japan, in Korea, in China, in journals American physicians do not routinely read.

The same effect did not appear for unfermented soy products. It was specific to the form containing nattokinase.

Nattokinase can also support arterial plaque breakdown, which improves blood flow and blood pressure. In a 2017 study by Ren et al., people who took it for several months had about a 36% reduction in plaque seen on ultrasound scans, showing real physical changes in the artery walls. Another study by Chen et al. found that higher doses led to noticeable plaque reduction, while lower doses did not, suggesting the amount you take matters.

This is the part where I have to be careful.

Nattokinase is real. The research is real. But most of the nattokinase capsules sold in America do not deliver what the label claims they do, for two reasons.

First, dosage. The clinical research uses 2,000 to 4,000 fibrinolytic units (FU) per day. A large number of products on the shelf deliver only 1,000 FU — half the studied dose — and rely on consumers not knowing the difference.

Second, delivery. Nattokinase is a fragile enzyme. Without a true acid-resistant capsule, your stomach acid breaks down most of it before it ever reaches the bloodstream. This is the reason most patients who try nattokinase off Amazon report they felt no difference. It is also the finding ConsumerLab’s independent testing has reported in this category.

And nattokinase performs better when paired with the cardiovascular co-factors the research consistently points to: CoQ10 for cellular energy in heart muscle (the molecule statins deplete), bromelain for circulatory support, turmeric and ginger for inflammation, olive leaf, and white willow bark.

The product I now point patients toward is called Hale Heart. It is the formula I have not been able to find anywhere else: a clinical 10,000 FU dose of nattokinase, the full cardiovascular co-factor stack above, and an actual acid-resistant capsule that gets the enzyme through the stomach and into the bloodstream intact. Every ingredient on the label with its exact dose. Third-party tested. Certificate of analysis published online for every batch.

It is not a miracle. Nothing is. But for patients who have had the scare, or who watched their father have it, and who want to do something serious for the long game — this is what I now tell them to start with.